Treatment of Siderosis
Critical Distinction: Type of Siderosis Determines Treatment
The treatment approach fundamentally differs based on whether you are managing superficial siderosis of the central nervous system versus systemic iron overload (hemochromatosis/hemosiderosis).
Superficial Siderosis of the CNS
Primary Treatment Strategy
Surgical closure of the dural defect is the definitive treatment for superficial siderosis, as it addresses the underlying cause of chronic subarachnoid bleeding. 1, 2
- The most common etiology is dural tears, often from disc disease, trauma, or surgical trauma 2
- Patients with dural tears from herniated/calcified discs frequently have ventral intraspinal fluid collections from CSF leak 2
- Precise identification requires multimodality imaging including CT myelography 2, 3
- Surgical correction combined with postoperative iron chelator administration appears to prevent hearing deterioration in some patients 1
Iron Chelation Therapy with Deferiprone
Deferiprone (15 mg/kg orally twice daily) is the iron chelator that can penetrate the blood-brain barrier and may be considered as adjunctive therapy, though evidence remains limited. 4, 5
Key evidence for deferiprone:
- Long-term observational data (average 3.7 years) showed clinical improvement in 2 of 4 patients with reduced postural instability and cerebellar signs 4
- All patients demonstrated reduction in abnormal iron deposition on MRI 4
- Treatment proved safe and well-tolerated 4
- One case report showed improvement in hearing and mobility following deferiprone treatment 5
Important caveat: Current data is insufficient to recommend routine use of deferiprone in all patients with superficial siderosis 2. Clinical outcomes are variable even with documented successful dural repair 2.
Clinical Monitoring
Comprehensive audiological assessment is essential, as hearing loss is a cardinal feature and can mimic age-related hearing loss, leading to misdiagnosis. 1
- Perform pure-tone audiometry, speech audiometry, and auditory brainstem response (ABR) testing 1
- Sensorineural hearing loss occurs in 84.8% of patients, typically presenting in the fifth to sixth decades 1
- Abnormal ABRs are observed in 82.6% of affected ears 1
- Long-term hearing prognosis can be predicted based on audiological changes within the first 12 months after initial visit 1
- Hearing deterioration of ≥10 dB occurs in 25.9% of ears during long-term follow-up (median 39 months) 1
Cochlear Implantation
Cochlear implantation shows limited effectiveness and should not be considered a primary treatment option. 1
Systemic Iron Overload (Hemochromatosis/Hemosiderosis)
Primary Treatment: Phlebotomy
Therapeutic phlebotomy is the first-line treatment for iron depletion in systemic iron overload. 6
Induction phase:
- Perform weekly or fortnightly phlebotomy until iron stores are depleted 6
- Target serum ferritin of 50 μg/L, but not lower to avoid iron deficiency 6
Maintenance phase:
- Maintain serum ferritin with flexibility in the range of 50-100 μg/L 6
Alternative to standard phlebotomy:
- Erythrocytapheresis is cost-effective during induction phase, requiring fewer interventions 6
- Personalized erythrocytapheresis is the preferred treatment in selected cases 6
Iron Chelation for Systemic Overload
If phlebotomy is not possible, iron chelation therapy can be started after careful risk-benefit consideration. 6
Deferasirox (DFX) considerations:
- Most evidence in hemochromatosis pertains to oral deferasirox as a possible second-line option 6
- DFX should NOT be used in patients with advanced liver disease 6
- Associated with gastrointestinal side effects and impaired kidney function 6
- Not approved for hemochromatosis treatment by the European Medicines Agency 6
Combined chelation therapy:
- In severe myocardial siderosis with left ventricular dysfunction (as in thalassemia major), combined deferiprone and deferoxamine therapy reduces myocardial iron and improves cardiac function 7
- This approach is less onerous than continuous high-dose deferoxamine monotherapy 7
Dietary and Lifestyle Modifications
Dietary modifications should NOT substitute for iron removal therapy but serve as important adjunctive measures. 6
Mandatory restrictions:
- Avoid iron supplementation and iron-fortified foods where possible 6
- Avoid supplemental vitamin C, especially before iron depletion (limit to 500 mg daily if necessary) 6
- Vitamin C can mobilize iron from reticuloendothelial stores and accelerate iron deposition, particularly dangerous in iron-overloaded patients 6
Strongly recommended restrictions:
- Limit red meat consumption (heme iron is well absorbed and bioavailability is little affected by meal composition) 6
- Restrict alcohol intake during iron depletion phase 6
- Patients with iron overload and/or liver abnormalities should avoid or consume very little alcohol 6
- Patients with cirrhosis must abstain from alcohol completely 6
Moderate restrictions:
- Consume fruit juices and citrus fruits in moderation, not in combination with other foods 6
Critical safety warning:
- In patients with hemochromatosis and iron overload, avoid direct handling and consumption of raw or undercooked shellfish and wound exposure to seawater due to risk of serious systemic infection by Vibrio vulnificus and other siderophilic pathogens in certain geographical regions 6
Monitoring During Treatment
Periodically check plasma folate and cobalamin, especially in patients requiring numerous venesections; administer vitamin supplements if necessary. 6